Boos Christopher J, Lip Gergory Y H
University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.
Front Biosci. 2006 Jan 1;11:328-36. doi: 10.2741/1800.
Worldwide, cardiovascular disease (CVD) is a leading cause of death. Endothelial dysfunction is now recognized to be a key platform for the pathophysiological effects of atherosclerosis. It is now well accepted that atherosclerosis is not merely a benign and passive process, but is in fact a dynamic and progressive disease arising from a combination of endothelial damage/dysfunction, inflammation, thrombosis and coagulation leading to potential clot-related vessel occlusion. The between inflammation, thrombosis and coagulation in the pathogenesis of CVD is more than simply association, as it clear that these processes are critically influenced by one another. In this preface we present a basic overview of the evidence in support of this relationship, which will be expanded upon in sequential chapters. In addition we briefly discuss a number of novel anticoagulants which not only reduce coagulation, but have ancillary antiinflammatory properties, thus further supporting the triad of inflammation, thrombosis and coagulation in the development of CVD.
在全球范围内,心血管疾病(CVD)是主要的死亡原因。内皮功能障碍现已被认为是动脉粥样硬化病理生理效应的关键平台。目前人们普遍认为,动脉粥样硬化不仅仅是一个良性的被动过程,实际上是一种动态的、渐进性疾病,由内皮损伤/功能障碍、炎症、血栓形成和凝血共同作用导致潜在的与血栓相关的血管阻塞。炎症、血栓形成和凝血在心血管疾病发病机制中的关系不仅仅是简单的关联,因为很明显这些过程相互之间有着至关重要的影响。在这篇前言中,我们将对支持这种关系的证据进行基本概述,后续章节将对此进行详细阐述。此外,我们还将简要讨论一些新型抗凝剂,它们不仅能减少凝血,还具有辅助抗炎特性,从而进一步支持了炎症、血栓形成和凝血在心血管疾病发展过程中的三联关系。